Recent Investment Analysts’ Ratings Updates for TELA Bio (TELA)

Share on StockTwits

TELA Bio (NASDAQ: TELA) recently received a number of ratings updates from brokerages and research firms:

  • 12/3/2019 – TELA Bio is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $17.00 price target on the stock.
  • 12/3/2019 – TELA Bio is now covered by analysts at JMP Securities. They set an “outperform” rating and a $22.00 price target on the stock.
  • 12/3/2019 – TELA Bio is now covered by analysts at Jefferies Financial Group Inc. They set a “buy” rating and a $23.00 price target on the stock.
  • 12/3/2019 – TELA Bio is now covered by analysts at Canaccord Genuity. They set a “buy” rating and a $19.00 price target on the stock.

Shares of TELA opened at $12.15 on Tuesday. TELA Bio has a 12 month low of $10.78 and a 12 month high of $15.05.

In other news, Director Matt Zuga bought 86,121 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were purchased at an average price of $12.09 per share, with a total value of $1,041,202.89. Also, major shareholder Orbimed Advisors Llc bought 384,615 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were purchased at an average cost of $12.09 per share, for a total transaction of $4,649,995.35.

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

Read More: What is the Shanghai Stock Exchange Composite Index?

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abbott Laboratories  Updates FY 2020
Pre-Market Earnings Guidance
Abbott Laboratories Updates FY 2020 Pre-Market Earnings Guidance
Express  Releases Q4 2019
Pre-Market Earnings Guidance
Express Releases Q4 2019 Pre-Market Earnings Guidance
MarineMax  Updates FY20 Earnings Guidance
MarineMax Updates FY20 Earnings Guidance
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Vanguard Russell 2000  Stock Position Trimmed by Janney Montgomery Scott LLC
Vanguard Russell 2000 Stock Position Trimmed by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris


 
© 2006-2020 Zolmax.